The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tse, H. M.
Right arrow Articles by Cooper, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tse, H. M.
Right arrow Articles by Cooper, A. M.
The Journal of Immunology, 2002, 168: 825-833.
Copyright © 2002 by The American Association of Immunologists

Activation of the Mitogen-Activated Protein Kinase Signaling Pathway Is Instrumental in Determining the Ability of Mycobacterium avium to Grow in Murine Macrophages1

Hubert M. Tse*, Steven I. Josephy*, Edward D. Chan{dagger},{ddagger}, Darren Fouts* and Andrea M. Cooper2,*

* Mycobacteria Research Laboratories, Department of Microbiology, Colorado State University, Fort Collins, CO 80523; {dagger} Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Boulder, CO 80206; and {ddagger} Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80262


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Of the two common morphotypes of Mycobacterium avium, designated smooth transparent (SmT) or smooth opaque (SmO), the SmO morphotype is avirulent, whereas the SmT morphotype is virulent. The role of the host macrophage in determining these different virulence phenotypes was analyzed using an in vitro model of macrophage infection. Initial studies confirmed previous reports of the increased ability of the SmT bacteria to grow in macrophages; this increased virulence correlated with reduced induction of inflammatory cytokines. Examination of the response of the mitogen-activated protein kinase (MAPK) pathway following infection with either morphotype revealed that all three members of the MAPK pathway were activated. Pharmacologic inhibition of either the extracellular signal-regulated kinase (ERK) or p38MAPK pathways resulted in distinct consequences for the growth of the two morphotypes. In particular, inhibition of the p38MAPK resulted in attenuated growth of the SmT morphotype, which correlated with reduced PGE2 production. Inhibition of cyclooxygenase 2 by indomethacin also inhibited growth of SmT, substantiating the role for PGE2 in promoting the growth of SmT. In contrast, SmO induction of the ERK pathway was increased compared with the SmT morphotype, and inhibition of ERK resulted in decreased TNF-{alpha} synthesis and enhanced SmO growth. Pharmacologic inhibitors of the MAPK pathway were present for only the first 4 h of infection and yet had consequences for bacterial growth at 7 days. Therefore, the data suggest that induction of the MAPK pathway during uptake of bacteria is instrumental in determining the eventual fate of the bacteria.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The facultative intracellular pathogen Mycobacterium avium causes opportunistic infections in AIDS patients and in other susceptible hosts such as individuals with emphysema (1, 2, 3, 4). M. avium can exhibit a variety of colony morphotypes when grown on agar, with the predominant morphotypes being either smooth transparent (SmT)3 or smooth opaque (SmO) in nature (5, 6). The SmT morphotype typically has greater virulence, antibiotic resistance, and prevalence of dissemination than the SmO morphotype (7, 8, 9). Although there are subtle differences in the nature of the major surface glycopeptidolipid and in certain proteins between the SmT and SmO morphotypes, the basis for the difference in virulence is not currently fully defined (10, 11, 12, 13).

The clinical observations regarding virulence of the morphotypes have been supported by studies using the SmT and SmO morphotypes in in vivo infection models of mice (7). The virulent SmT morphotype grows progressively for some time before being limited, but not cleared, by acquired cellular responses. In contrast, the isogenic avirulent SmO morphotype is rapidly cleared from the infected animal (7, 14). The mechanisms underlying the differences in virulence between these two morphotypes have not been defined either at the level of the host response or by the identification of M. avium virulence factors. However, previous studies have identified the cytokine TNF-{alpha} as being differentially induced and differentially protective during infection with the two morphotypes (15, 16, 17, 18). Induction of other cytokines by the two morphotypes is also different, with the SmT bacteria being less stimulatory (19, 20). This reduced stimulatory activity of the SmT morphotype is a potential virulence factor and may result from modulation of macrophage receptor-mediated stimulation by molecules unique to the SmT morphotype.

The initial interaction between host macrophages and bacteria results in the induction of intracellular signaling pathways that connect receptor-mediated events to transcriptional responses within the nucleus. In eukaryotic cells, an important group of signaling pathways is the mitogen-activated protein kinase (MAPK) signaling cascades. MAPKs are comprised of three principal serine threonine kinases with multiple subisoforms within each member: p38MAPK with subisoforms {alpha}, {beta}, {gamma}, and {delta}; extracellular signal-regulated kinase (ERK) 1/2 with p44 (ERK1) and p42 subisoforms; and c-Jun NH2-terminal kinase (JNK) or stress-activated protein kinase with two principal subisoforms, p46 JNK1 and p54 JNK2. Previous studies have implicated the MAPKs in bacterial pathogenesis as evidenced by their induction or inhibition by Salmonella typhimurium (21), Yersinia sp. (22, 23, 24), and Listeria monocytogenes (25, 26).

We hypothesized that the virulence of the SmT morphotype was linked to events occurring during the induction of macrophage activation and that modulation of that activation would reduce the virulence of the SmT bacteria. To test these hypotheses, we chose to examine the activation of the MAPK pathway by the clinical isolate of M. avium designated 2151 (serovar 2), which exists as stable SmT and SmO morphotypes (27). These morphotypes exhibit the expected virulence phenotypes in vivo (A. M. Cooper, unpublished observation). We observed that both the SmO and the SmT morphotypes of M. avium activated the principal components of the MAPK pathway. However, pharmacological inhibition of the p38MAPK resulted in reduced virulence of the SmT morphotype, whereas inhibition of the ERK pathway resulted in slightly enhanced growth of the avirulent SmO morphotype.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Materials

Female C57BL/6 mice 6–8 wk in age were purchased from The Jackson Laboratory (Bar Harbor, ME) and were used as a source for bone marrow-derived macrophages. Phospho-p38MAPK (Thr180/Tyr182), phospho-JNK (Thr183/Tyr185), phospho-Akt (Ser473), phospho-Akt (Thr308), and Akt Abs were purchased from Cell Signaling (Beverly, MA). Phospho-ERK (E-4), JNK1 (F-3), ERK1 (K-23), and p38MAPK (N-20) Abs were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-mouse IL-10, anti-mouse TNF-{alpha}, and rat isotype IgG1 control Abs were purchased from BD PharMingen (San Diego, CA). SB203580, PD98059, and indomethacin were from Calbiochem (La Jolla, CA).

Isolation of mouse bone marrow-derived macrophages

Bone marrow-derived macrophages were cultured as described previously (28) using complete media comprised of DMEM supplemented with 10% heat-inactivated FCS, 10% L-929 cell-conditioned medium, 10 mM HEPES buffer, 2 mM L-glutamine, 2x nonessential amino acids, and 1% penicillin/streptomycin/amphotericin B (complete DMEM; Sigma-Aldrich, St. Louis, MO). Six- and 24-well tissue culture plates were initially seeded with 4 x 106 cells/well and 1 x 106 cells/well, respectively, and incubated at 37°C in a 5% CO2 humidified air chamber for 24 h. The following day, the macrophages were supplemented with an additional 4 or 1 ml/well of complete DMEM for the 6- or 24-well plates, respectively. The cultures were incubated for a total of 7–10 days at 37°C in a 5% CO2 humidified air chamber with a change of fresh complete DMEM every 2 days. Twenty-four hours before infection, the macrophages were washed twice with PBS and were then replenished with incomplete DMEM (complete DMEM lacking 10% L-929 conditioned medium and antibiotics).

Growth and isolation of M. avium strains

M. avium 2151 was originally isolated from an AIDS patient, and both the SmT and SmO morphotypes were used. The morphotypes were picked from 7H11 agar (Difco, Detroit, MI) plates supplemented with Middlebrook oleic acid dextrose complex and were expanded on similar plates at 37°C for 10–14 days. The cells were harvested by scraping the plates with a sterile cotton swab stick and they were resuspended in 7H9 broth containing 0.04% Tween 80. The cell suspension was dispersed of bacterial clumps by stirring with a flea bar at room temperature for several hours and it was then frozen at -70°C in 2-ml aliquots. The concentration and morphotypes of the frozen stocks were confirmed by performing serial dilutions on 7H11 agar quad plates containing oleic acid dextrose complex and they were then incubated at 37°C for 10–14 days.

In vitro infection of bone marrow-derived macrophages

Macrophages in 6- and 24-well plates were infected with a suspension of M. avium 2151 SmT or SmO in incomplete DMEM at a multiplicity of infection (MOI) of 2:1. In certain wells, macrophages were first pretreated with 1, 10, or 30 µM SB203580 or PD98059, or 1, 10, or 20 µM indomethacin for 60 min before infection. To serve as a control, the volume of the diluent DMSO contained in 30 µM SB203580 or PD98059 was added to the cell culture. Twenty-four-well macrophage cultures were infected for 4 h at 37°C, washed five times with PBS to remove nonadherent bacteria, and then replenished with 1 ml of incomplete DMEM per well (no inhibitors were added following the initial 4-h infection period). After this initial uptake period (4 h), the number of phagocytosed bacteria was determined by lysing macrophages using osmotic shock and plating the lysate on 7H11 agar at 37°C. The number of bacteria phagocytosed by macrophages over the 4 h of incubation was reproducible and was not altered by the presence of inhibitors (data not shown). The bacterial count made after 4 h of incubation is shown as t = 0 on the graphs. That bacteria were being phagocytosed was confirmed by fluorescent microscopy using the TB Fluorescent Stain kit M (BD Biosciences Microbiology Systems, Sparks, MD; data not shown). Macrophages were subsequently lysed at days 3 and 7 postinfection to quantitate the growth of the bacteria. Due to the low MOI, macrophages were not susceptible to apoptosis following infection, nor did SB203580, PD98059, or indomethacin adversely affect macrophages. Viability of cell cultures was based on trypan blue dye exclusion and by MTT-formazan assay (data not shown).

Preparation of cell lysates

Bone marrow-derived macrophages prepared as above and cultured in six-well tissue culture plates were infected with M. avium 2151 SmT or SmO (MOI of 2:1). At various time points immediately postinoculation, the macrophages were washed with ice-cold PBS and cellular extracts were harvested using a lysis buffer containing 50 mM Tris-base, pH 8.0, 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, 1 mM NaF, 5 mg/ml leupeptin, 5 mg/ml aprotinin, 2 mM Na3VO4, and 1 mM PMSF, all purchased from Sigma-Aldrich. After the addition of 500 µl of lysis buffer per well, the macrophages were incubated on ice for 10 min, scraped, and transferred to a 1.5-ml centrifuge tube. Nuclei were spun down in an Allegra 21R refrigerated microcentrifuge (Beckman Coulter, Palo Alto, CA) at 17,000 x g for 10 min at 4°C and the supernatant (whole cell lysate) was collected. The protein concentration of the whole cell lysate was determined by the bicinchoninic acid protein assay according to the manufacturer’s instructions (Pierce, Rockford, IL).

p38MAPK, JNK, ERK, and PKB/Akt Western immunoblotting and in vitro ERK assay

After stimulation and lysis of the macrophages, 20 µg of whole cell lysate from each sample was separated on a 10% SDS-PAGE and transferred onto 0.45-µm nitrocellulose PROTRAN membranes using a Panther semidry transfer apparatus (model HEP-1; Owl Separation Systems, Portsmouth, NH) at 12 V for 1 h in 25 mM Tris-HCl, 192 mM glycine, and 20% methanol, pH 8.3. When using phospho-specific Abs, the nitrocellulose membranes were blocked in 5% milk in PBS containing 0.05% Tween 20 (PBST) for 1 h at room temperature. The membranes were incubated overnight at 4°C with anti-phospho-p38MAPK Ab or anti-phospho-JNK, anti-phospho-ERK, or anti-phospho-Akt in 5% BSA in PBST. The membranes were then washed four times for 5 min in PBST and incubated with goat anti-rabbit polyclonal Ab conjugated to HRP in 5% milk in PBST for 1 h at room temperature. Chemiluminescence was detected using the ECL plus reagent (Amersham Pharmacia Biotech, Little Chalfont, U.K.) according to the manufacturer’s recommended protocol.

Western immunoblotting for total p38MAPK, ERK, JNK, or Akt was performed on the same nitrocellulose membranes that had been probed with phospho-specific Abs by rinsing with PBST and then blocking with 5% BSA in PBST for 1 h at room temperature. The membranes were probed overnight at 4°C with anti-p38MAPK (N-20), anti-JNK1 (F-3), anti-ERK1 (K-23), or anti-Akt Abs 5% BSA in PBST. Membranes were then washed four times with PBST for 5 min and were incubated with either anti-mouse or anti-rabbit IgG HRP-conjugated Abs (Santa Cruz Biotechnology) in PBST for 1 h at temperature. The immunoblots were detected with ECL plus as described above. An in vitro ERK activity assay kit using Elk-1 as the substrate was purchased from Cell Signaling and was performed according to the manufacturer’s protocol.

Anti-IL-10 and anti-TNF-{alpha} treatment of infected macrophages

Bone marrow-derived macrophages were preincubated with 10 µg/ml anti-mouse IL-10 or 5 µg/ml anti-mouse TNF-{alpha} Abs for 30 min before infection with M. avium 2151 SmT or SmO as described above. After the 4-h infection, macrophages were washed three times with PBS and were then replenished with antibiotic-free DMEM without the anti-mouse IL-10 or anti-mouse TNF-{alpha} Abs. The number of viable bacteria was determined at 4 h and 3 and 7 days postinfection by lysing infected macrophages by osmotic shock. The cell lysate containing viable bacteria was diluted and plated onto 7H11 quad plates as described above.

ELISAs

TNF-{alpha} and PGE2 produced in the supernatants from infected macrophages were measured using commercial ELISA kits from R&D Systems (Minneapolis, MN) and Cayman Chemicals (Ann Arbor, MI), respectively. IL-6 and IL-12p40 ELISAs were performed according to a standard protocol from BD PharMingen. Streptavidin-conjugated HRP (Zymed Laboratories, San Francisco, CA) was used at a final dilution of 1/4000, and tetramethylbenzidine was used according to the manufacturer’s protocol (DAKO, Carpinteria, CA). ELISA plates were analyzed for absorbance at 450 nm using a VersaMax microplate reader and SOFTmax PRO software (Molecular Devices, Sunnyvale, CA).

Nitrite assay

NO2- production was measured by adding 50 µl of Greiss reagent (1% sulfanilamide and 0.1% naphthylethylenediamide in 5% phosphoric acid) to 50 µl of supernatant obtained from M. avium-infected macrophage culture as described previously (29). The NO2- concentration was determined by comparing the optical density at 550 nm with a standard curve generated from various known concentrations of sodium nitrite dissolved in culture medium.

Statistical analysis

Determination of the difference between mean values for each experimental group were assessed by the Student t test, with p < 0.05 considered significant. All experiments were performed at least three separate times with data obtained in duplicate wells in each experiment.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The SmT morphotype of M. avium can proliferate within macrophages, whereas the SmO morphotype can merely persist

The growth phenotype of the morphotypes derived from M. avium strain 2151 has not previously been described; therefore, bacteria were added to macrophages and internalization and growth were determined. As shown in Fig. 1Go, both SmT and SmO were equally infective (t = 0). Following 3 days in culture, the SmO bacteria had reduced in number slightly, whereas the SmT bacteria persisted at levels equal to the initial infection. By 7 days of infection, the phenotype was more defined, with the SmT exhibiting a 10-fold increase in number compared with an absence of growth for the SmO bacteria.



View larger version (16K):
[in this window]
[in a new window]
 
FIGURE 1. Growth curves of M. avium 2151 SmT and SmO in bone marrow-derived macrophages over 7 days of culture. Macrophages were infected with M. avium morphotypes at an MOI of 2:1. M. avium morphotype SmO was unable to grow within the macrophages, whereas the SmT morphotype proliferated 10-fold over the 7-day culture period. Results are representative of the mean (±SEM) of four independent experiments each performed in triplicate. ***, p < 0.001 vs M. avium 2151 SmO-viable bacteria at day 7.

 
Exposure of macrophages to bacteria of the SmO morphotype resulted in pronounced production of the cytokines IL-12p40 and IL-6

To determine whether the SmT and SmO M. avium 2151 morphotypes were inducing different levels of macrophage activation following infection, the production of cytokines and NO was followed over time. As expected, SmO-infected macrophages induced higher levels of IL-6, IL-12p40, and reactive nitrogen intermediates when compared with SmT-infected macrophages (Fig. 2Go, AC). However, it is important to note that IL-12p40, IL-6, and TNF-{alpha} were all induced by the SmT infection (Fig. 2Go).



View larger version (35K):
[in this window]
[in a new window]
 
FIGURE 2. M. avium 2151 SmO-infected macrophages demonstrate an increased cytokine response. Culture supernatants from SmT- and SmO-infected macrophages were harvested just before and at the indicated hours following infection and were analyzed for IL-6, IL-12p40, TNF-{alpha}, and NO2- levels by ELISA or Griess assay. Compared with uninfected macrophages, both SmO- and SmT-infected macrophages expressed higher levels of IL-6 (A), IL-12p40 (B), and TNF-{alpha} (D) throughout the time course of infection, whereas only SmO-infected macrophages induced detectable NO2- (C). SmT induction of both IL-6 and IL-12p40 was reduced when compared with the induction mediated by the SmO infection. Results are representative of the mean (±SEM) of at least four independent experiments, each performed in duplicate. ***, p < 0.001; *, p < 0.05 vs M. avium 2151 SmT-infected macrophages.

 
TNF-{alpha} was induced to comparable levels by both morphotypes during the first 4 h of infection (Fig. 2GoD). After the wash to remove extracellular bacteria at 4 h, little to no TNF-{alpha} could be detected in response to either morphotype (data not shown). This observation may relate to the reportedly reduced ability of this particular strain to induce secreted TNF-{alpha} (16, 18).

Although both morphotypes could induce macrophage activation, the observed differences may reflect altered stimulation of the signal transduction pathways involved in macrophage activation.

p38MAPK, ERK, and JNK are phosphorylated following interaction of macrophages with either SmT or SmO morphotypes

The MAPK signaling pathways have been implicated in mediating the expression of a wide variety of cytokines in cells stimulated with bacterial products (30). To compare the ability of the SmT and SmO morphotypes to induce macrophage MAPKs, activation of p38MAPK, ERK, and JNK was analyzed directly upon infection. Western blot analysis of cell lysates using Abs specific for the activated, (i.e., phosphorylated) forms of the MAPKs proteins revealed that all three MAPKs were activated as early as 15 min following infection (Fig. 3Go, AC). Interestingly, the SmO-infected macrophages demonstrated an ~3-fold increase in phosphorylation of ERK in comparison with SmT-infected macrophages at 60 and 120 min postinfection (Fig. 3GoB). Fig. 3GoD shows that the increased phosphorylation of the ERK protein seen in the SmO-stimulated cells translates into increased ERK activity. In contrast, the level and kinetics of p38MAPK and JNK1/2 phosphorylation (Fig. 3Go, A and C, respectively) were similar for macrophages infected with either morphotype.



View larger version (40K):
[in this window]
[in a new window]
 
FIGURE 3. p38MAPK, ERK, and JNK are activated following infection of macrophages with M. avium 2151 SmT or SmO. Whole cell lysates (20 µg of protein) from macrophages infected with SmT or SmO (MOI 2:1) for 15, 30, or 60 min were separated by SDS-PAGE and immunoblotted with phospho-specific Abs to p38MAPK, ERK, and JNK. All three MAPKs were activated following infection or with (100 ng/ml) LPS treatment with no observable difference in the levels of phospho-p38MAPK (A) or phospho-JNK (C) between the SmT or SmO morphotypes after 15, 30, or 60 min postinfection. Unstimulated macrophages exhibited a basal level of ERK phosphorylation (B), but SmO-infected macrophages induced a 3-fold increase in phospho-ERK protein at 60 min postinfection in comparison with SmT-infected macrophages, and this correlated with an increase in ERK activity (D) at 60 min postinfection as demonstrated by an in vitro ERK assay. Equivalent levels of protein were separated in each of the lanes as demonstrated by immunoblots against total p38MAPK, ERK, or JNK protein (AC, bottom). The results are representative of three independent experiments. Data shown represent points when differences were observed; not all time points or concentrations are shown, although they were performed.

 
Inhibition of the growth of the SmO morphotype is mediated via MEK1-ERK and TNF-{alpha}

The increased ERK activation by the SmO morphotype suggested that this pathway might play a role in the control of these bacteria. To assess whether this was the case, PD98059, a specific inhibitor of MAPK kinase (MEK)1, the upstream kinase of ERK, was added to macrophages. Although PD98059 was present for only the first 4 h of infection, a clear effect on bacterial growth was seen at 3 and 7 days (Fig. 4GoA). More specifically, in macrophages treated with 30 µM PD98059, there was a 4-fold increase in viable CFU of the SmO morphotype at 7 days in culture (Fig. 4GoA), whereas no significant effect on SmT growth was observed (data not shown). In addition, 30 µM PD98059 prevented SmO-induced ERK phosphorylation in macrophages (data not shown).



View larger version (21K):
[in this window]
[in a new window]
 
FIGURE 4. ERK attenuates the growth of the SmO morphotype by mediating SmO-induced synthesis of TNF-{alpha}. A, The SmO bacteria exhibit limited but reproducible growth in the presence of PD98059 (*, p < 0.05 compared with the DMSO vehicle). B, TNF-{alpha} protein production in response to M. avium SmO is reduced in the presence of PD98059. Results are representative of the mean (±SEM) of three independent experiments, each of which was performed in duplicate. *, p < 0.05 vs DMSO-treated macrophages. ***, p < 0.001 vs DMSO-treated macrophages.

 
ERK is involved in induction of TNF-{alpha} (31), and thus the effects of 30 µM PD98059 on TNF-{alpha} expression were assessed. Infection of macrophages with SmO resulted in TNF-{alpha} expression at 4 h postinfection (Fig. 2GoD), and macrophages coincubated with 30 µM PD98059 exhibited a significant 5-fold inhibition of TNF-{alpha} expression at this time point (Fig. 4GoB).

To confirm that the TNF-{alpha} induced by ERK was responsible for control of the avirulent SmO morphotype, macrophages were pretreated with anti-TNF-{alpha} Ab for 30 min before and for the 4-h infection process, after which it was washed away. As shown in Table IGo, although Ab was present only during the initial interaction of bacteria and macrophages, treatment with anti-TNF-{alpha} Ab increased the growth of SmO at day 7 by a significant and reproducible degree (p < 0.05).


View this table:
[in this window]
[in a new window]
 
Table I. Increase in CFU following anti-TNF-{alpha} treatment of SmO- but not SmT-infected bone marrow-derived macrophages

 
The inability of ERK inhibition to affect the growth of the SmT morphotype suggests that the bacteria are, unlike the SmO bacteria, resistant to the effects of TNF-{alpha}-mediated macrophage activation. Conversely, SmT bacteria may induce TNF-{alpha} with impunity due to their ability to down-regulate macrophage activation directly. This possibility is addressed in the following section.

Induction of the p38MAPK pathway is a requirement for the optimal growth of SmT bacteria

The observed difference in cytokine induction by the two morphotypes (Fig. 2Go) suggested that although SmT bacteria are capable of activating the macrophage, they may also induce other molecules capable of moderating macrophage activation. To address whether the MAPKs were involved in induction of a down-regulatory pathway following SmT infection, the inhibitor of p38MAPK phosphorylation, SB203580, was used. As shown in Fig. 5Go (top), a significant decrease in SmT growth was observed at 7 days postinfection as a result of preincubation of the macrophages with SB203580. This occurred despite the fact that SB203580 was washed away following the initial 4-h treatment. The decrease in SmT growth was not due to SB203580 toxicity, as macrophages were viable at all concentrations of SB203580 tested as determined by an MTT-formazan assay (data not shown). In addition, in macrophages treated with SB203580, there was little or no effect on SmO survival (Fig. 5Go, bottom).



View larger version (16K):
[in this window]
[in a new window]
 
FIGURE 5. Inhibition of p38MAPK enhances killing of M. avium 2151 SmT. Macrophages were pretreated with 30 µM SB203580 or with DMSO for 1 h before infection with M. avium 2151 SmT (top panel) or SmO (bottom panel) at MOI of 2:1. Growth of SmT bacteria was reduced, whereas the survival of the SmO bacteria was unaffected. The results represent the mean (±SEM) of five independent experiments performed, each of which was performed in triplicate. *, p < 0.05 vs DMSO control.

 
That the SmO bacteria were unable to take advantage of the inhibition of p38MAPK suggests that there are other antibacterial mechanisms active against the SmO bacteria that do not affect the SmT bacteria.

IL-10 is not required for bacteria of the SmT morphotype to grow in macrophages

That inhibition of p38MAPK activation resulted in reduced virulence of the SmT morphotype suggests that this morphotype may actively induce down-regulatory molecules. In particular, the reduced induction of IL-12p40 implicates the known inhibitor of IL-12p40, IL-10. In addition, the p38MAPK pathway has been shown to elicit an immune suppressive macrophage phenotype through the induction of IL-10 (32, 33). To determine whether this cytokine was important in permitting SmT growth, infected macrophages were cultured with anti-IL-10 Ab during the infection process. As expected and as confirmation that the anti-IL-10 was functioning, anti-IL-10 (10 µg/ml) treatment enhanced IL-12p40 synthesis 5-fold in SmT-infected macrophages (data not shown). However, interestingly, the addition of anti-IL-10 Ab to M. avium 2151 SmT- (Fig. 6GoA) or SmO-infected macrophages (data not shown) did not change the in vitro growth characteristics of either strain. The inability of anti-IL-10 to affect bacterial growth suggests that although IL-10 is produced and does down-regulate IL-12p40 production by SmT-infected macrophages, its induction is not an important factor in the virulence of SmT.



View larger version (17K):
[in this window]
[in a new window]
 
FIGURE 6. Early neutralization of IL-10 has no effect on the growth of SmT in macrophages. Macrophages were incubated with 10 µg/ml of IgG or anti-IL-10 for 1 h before and during the first 4 h of infection with the SmT morphotype (MOI of 2:1). No significant differences in bacteria growth were detected in the presence of the anti-IL-10 Ab. Results are representative of the mean (±SEM) of three independent experiments performed in duplicate.

 
Macrophages infected with SmT express PGE2 in a p38MAPK pathway-dependent fashion

Other mediators of macrophage down-regulation are the PGs, specifically PGE2 and PGI2. In addition, the p38MAPK-signaling cascade is known to regulate the synthesis of PGs at the arachidonic acid substrate level and also at the level of cyclooxygenase-2 mRNA stability (34, 35). In support of a role for PGE2 in mediating the increased growth of the SmT, this molecule was detected in the supernatant of infected macrophages as early as the first hour of infection. By 4 h, the level was significantly higher than the level seen for the SmO-infected macrophages (Fig. 7Go). Further in support of the hypothesis was the observation that increasing concentrations of the p38MAPK inhibitor, SB203580, significantly decreased the induction of PGE2 by both morphotypes (Fig. 7Go, upper right panel and lower panel).



View larger version (26K):
[in this window]
[in a new window]
 
FIGURE 7. Synthesis of PGE2 by SmO- and SmT-infected macrophages is inhibited by SB203580. Macrophages were incubated with DMSO or 1, 10, or 30 µM SB203580 for 1 h before infection with M. avium 2151 SmT or SmO for 4 h at a MOI of 2:1. The release of PGE2 into the supernatant, as detected by ELISA, was reduced in the presence of SB203580. Results are representative of the mean (±SEM) of three independent experiments done in duplicates. *, p < 0.05 vs DMSO-treated macrophages; §, p < 0.05 vs SmO-infected macrophages

 
Inhibition of PGE2 by indomethacin results in decreased ability of the SmT bacteria to grow within infected macrophages

To confirm the role of PGE2 synthesis in increased growth of the SmT morphotype, macrophages were treated with the cyclooxygenase inhibitor, indomethacin, before and for the 4-h infection with SmT and SmO bacteria. At all concentrations of indomethacin (1, 10, or 20 µM) tested, the growth of the SmT morphotype 7 days postinfection was decreased 3-fold (Fig. 8Go, top; only 10 µM data are shown for clarity). Interestingly, indomethacin treatment did not have an effect on the survival of the SmO morphotype within bone marrow-derived macrophages (Fig. 8Go, bottom). As expected, PGE2 levels decreased to basal levels in the presence of indomethacin (data not shown).



View larger version (19K):
[in this window]
[in a new window]
 
FIGURE 8. Indomethacin reduces growth of M. avium 2151 SmT within bone marrow-derived macrophages. Macrophages were preincubated with 10 µM indomethacin for 1 h before and during SmT or SmO infection (MOI of 2:1). Indomethacin decreased the viable CFU of the SmT morphotype at least 3-fold (upper panel), with no significant effect on the viability of the SmO morphotype (lower panel). Results are representative of the mean (±SEM) of four independent experiments, each of which was performed in triplicate. *, p < 0.05 vs vehicle-treated macrophages.

 
SmT- and SmO-induced activation of the PKB/Akt pathway is inhibited in the presence of 30 µM SB203580

Although significant and distinct effects on the growth of each morphotype were seen in the presence of inhibitors of both the ERK and p38MAPK MAPK pathways, the only difference between the induction of MAPK pathways by SmO and SmT bacteria was the increased ERK activation by SmO. Although this may explain the specific effect of the ERK inhibitor on the increased growth of SmO, it does not support a unique role for the p38MAPK pathway in SmT virulence. It is likely that other signaling pathways are induced during phagocytosis of M. avium and that these pathways modulate the consequences of p38MAPK pathway activation. In addition, the pharmacological inhibitor of p38MAPK used in this study is known to inhibit activation of phosphoinositide-dependent protein kinase 1, the upstream protein kinase of the protein kinase B (PKB)/Akt signaling pathway (36). In determining whether this was the case in M. avium-infected macrophages, we found that both SmT- and SmO-infected macrophages expressed phosphorylated-Akt as early as 15 min after infection. Of particular interest was the observation that in the presence of 30 µM SB203580, this induction of the Akt pathway was inhibited (Fig. 9GoA).



View larger version (34K):
[in this window]
[in a new window]
 
FIGURE 9. SB203580 inhibits both SmT- and SmO-induced PKB/Akt phosphorylation and enhances SmT- and SmO-induced JNK and ERK phosphorylation. A, Macrophages were serum-starved for 24 h and preincubated for 1 h with DMSO or 30 µM SB203580 before infection with SmT or SmO (MOI of 2:1) for 15 min. B, Macrophages were pretreated with DMSO or 1, 10, or 30 µM SB203580 for 1 h before being infected with SmT or SmO (MOI of 2:1) for 15 min. C, Whole cell lysates from infected and control or SB203580-treated macrophages were immunoprecipitated with immobilized phospho-ERK Ab, followed by an in vitro ERK assay using Elk-1 as the substrate. The presented data are representative of three independent experiments. Data shown represent points when differences were observed; not all time points or concentrations are shown, although they were performed.

 
In addition to the inhibitory effects of SB203580 on the PKB/Akt pathway, we also observed enhanced JNK and ERK activation when macrophages were treated even with 1 µM of SB203580. The increase in SmO- and SmT-induced ERK activity at 15 min of infection (Fig. 9GoC) occurs before the difference between ERK activation in SmO and SmT untreated macrophages is seen (Fig. 3GoC). Increased phosphorylation of JNK1/2 also resulted from SB203580; however, we were unable to address the role of this pathway in the current study (Fig. 9GoB).


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The response of macrophages to invasion by intracellular pathogens depends to an extent upon the signals initiated during phagocytosis. In this study, we have identified some of the pathways induced during uptake of M. avium, and we have linked the induction of these pathways to the ability of the bacteria to grow in macrophages. Of particular interest was the observation that the virulent morphotype of M. avium activates macrophages, but that this activation is reduced by the p38MAPK-dependent production of PGE2. In contrast, the avirulent morphotype induces greater activation of macrophages, and its growth appears to be controlled, to some extent, by the induction of ERK and the production TNF-{alpha}. Taken together, the data suggest that the initial induction of the MAPK pathway by the morphotypes is a contributory factor in determining the fate of the M. avium morphotypes in macrophages.

We had hypothesized that very early interactions between the macrophage and the SmT bacteria were responsible for the virulence of this morphotype. We found this to be true in that inhibition of the p38MAPK pathway during the first 4 h of infection had profound effects on the ability of the bacteria to grow over the following 7-day period. The ability of the virulent SmT to down-regulate macrophage activation is the most obvious explanation for its increased virulence. In studying this inhibitory activity of the SmT morphotype, we describe in this study that both IL-10 and PGE2 were acting on the macrophages to down-regulate IL-12p40 induction and antimycobacterial activity, respectively. Three lines of evidence support a role for PGE2 in mediating SmT virulence. First, SmT-infected macrophages expressed an increased level of PGE2 compared with SmO-infected macrophages. Second, pretreatment with the p38MAPK inhibitor, SB203580, prevented PGE2 synthesis after SmT infection and enhanced macrophage control of SmT. Finally, treatment of SmT-infected macrophages with indomethacin (an independent inhibitor of PGE2 expression by inhibition of cyclooxygenase-1 and -2 activity) also diminished SmT viability 5-fold. The relevance of this observation to clinical disease is highlighted by a case report showing that monocytes from a 3-year-old girl with disseminated M. avium infection demonstrated a defect in bactericidal activity that was restored when the patient was treated with indomethacin (37). In addition, HIV infection may augment M. avium infection through a similar mechanism, as the HIV envelope glycoprotein (gp120) can enhance M. avium replication within macrophages by induction of PGE2 (38).

The inhibition of p38MAPK activation by SB203580 resulting in decreased cyclooxygenase-2 activity and thus production of PGE2 has been previously reported (39). In addition, the SmT-mediated induction of PGE2 was inhibited by a concentration of SB203580 close to the reported physiological inhibitory concentration of SB203580 for p38MAPK (40), supporting the hypothesis that PGE2 induction was dependent upon activation of p38MAPK. However, it is possible that the SB203580 was acting directly on the enzymes cyclooxygenase-1 and -2 required for synthesis of PGs, as has been previously shown to occur in platelets (41). This direct activity occurs at a higher concentration of SB203580 (30 µM; Ref. 41), which is the same concentration at which we detected significantly decreased growth of the SmT bacteria. Therefore, it is plausible that although inhibition of PGE2 can occur at the lower concentration of SB203580, the higher concentration is required to directly inhibit its production. That the direct inhibitor of the cyclooxygenase enzymes, indomethacin, was a more potent inhibitor of SmT virulence further supports the role of these enzymes in SmT virulence.

Although the evidence suggests that p38MAPK-mediated induction of PGE2 is an important mediator of increased SmT growth, it is possible that the higher levels of SB203580 required to inhibit growth may affect other macrophage signaling pathways. Indeed, there is growing evidence that the use of this pyridinyl imidazole compound at high concentrations results in the inhibition of several signaling and metabolic pathways (36, 41, 42). At the higher concentration of SB203580, we observed inhibition of the PKB/Akt pathway as shown by reduced phosphorylation of phosphoinositide-dependent protein kinase 1 (also reported in Ref. 36). The PKB/Akt pathway regulates programmed cell death, and apoptosis has been implicated as a method by which macrophages limit mycobacterial growth. Interestingly, we were not able to detect any decrease in cell viability as determined by trypan blue exclusion or MTT-formazan assay (data not shown) following M. avium infection either in the presence or absence of SB203580. It is likely that the low MOI and the strain of M. avium used greatly reduced the tendency of the bacteria to induce apoptosis in the model reported in this study (43, 44, 45).

An alternative mechanism by which inhibition of the PKB/Akt pathway by SB203580 results in decreased SmT viability may be via the repressive effects of PKB/Akt on the Raf-MEK-ERK pathway (46, 47). PKB/Akt has been shown to phosphorylate Raf-1 at a conserved serine residue in the catalytic domain and to prevent the phosphorylation of MEK, the upstream protein kinase and activator of ERK (46). That this mechanism may be active in our model is suggested by our observation that ERK and JNK are up-regulated following SB203580 treatment and by the reported inhibitory effect of the p38MAPK on the ERK and JNK pathways (48, 49, 50). Interestingly, we also noted increased ERK activity in the SmO-infected macrophages when compared with the SmT-infected macrophages, suggesting that p38MAPK-dependent inhibition of ERK may be another defense mechanism of the SmT morphotype.

The data suggest that the SmO bacteria induce enhanced ERK activation, resulting in TNF-{alpha} production and macrophage activation, which in turn contributes to the control of bacterial growth. In contrast, although the virulent SmT bacteria induce ERK, they also induce a p38MAPK dependent inhibitory pathway that results in the expression of IL-10, PGE2, and the down-regulation of ERK. The induction of PGE2 is a contributing factor in the ability of the SmT bacteria to grow.

In conclusion, we have shown that pharmacological modulation of the MAPK pathway for only the first 4 h of the macrophage-mycobacterial interaction results in consequences in bacterial growth up to 7 days later. This demonstrates that the very earliest signals initiated during uptake of the bacteria contribute to the environment in which the bacteria exist throughout infection. The response of the two morphotypes to the intracellular environment is likely to be distinct and, thus, the same protective mechanisms induced by the SmT bacteria may fail to enhance growth of the SmO bacteria. However, this difference in bacterial response to macrophage defense mechanisms is outside the scope of the work reported in this study. The more we understand the mechanisms by which mycobacteria subvert the protective immune response, the easier it will be to both vaccinate against disease and to design novel therapeutics. The data presented in this study suggest that the use of indomethacin and other inhibitors of PGE2 may be useful in treating chronic M. avium infections.


    Footnotes
 
1 This work was supported by the National Institutes of Health (Award AI-41922). Back

2 Address correspondence and reprint requests to Dr. Andrea M. Cooper, The Trudeau Institute, 100 Algonquin Way, Saranac Lake, NY 12983. E-mail address: acooper{at}trudeauinstitute.org Back

3 Abbreviations used in this paper: SmT, smooth transparent; SmO, smooth opaque; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; JNK, c-Jun NH2-terminal kinase; MOI, multiplicity of infection; MEK, MAPK kinase; PKB, protein kinase B. Back

Received for publication July 30, 2001. Accepted for publication November 6, 2001.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Horsburgh, C. R., R. M. Selik. 1989. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immune deficiency syndrome (AIDS). Am. Rev. Respir. Dis. 139:4.[Medline]
  2. Young, L. S.. 1988. Mycobacterium avium complex infection. J. Infect. Dis. 157:863.[Medline]
  3. Ellner, J. J., M. J. Goldberger, D. M. Parenti. 1991. Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. J. Infect. Dis. 163:1326.[Medline]
  4. Inderlied, C. B., C. A. Kemper, L. E. Bermudez. 1993. The Mycobacterium avium complex. Clin. Microbiol. Rev. 6:266.[Abstract/Free Full Text]
  5. Vestal, A. L., G. P. Kubica. 1966. Differential colonial characteristics of mycobacteria on Middlebrook and Cohn 7H10 agar-base medium. Am. Rev. Respir. Dis. 94:247.[Medline]
  6. Fregnan, G., D. Smith, H. Randall. 1962. A mutant of a scotochromogenic Mycobacterium detected by colony morphology and lipid studies. J. Bacteriol. 83:828.[Abstract/Free Full Text]
  7. Schaefer, W. B., C. L. Davis, M. L. Cohn. 1970. Pathogenicity of transparent, opaque, and rough variants of Mycobacterium avium in chickens and mice. Am. Rev. Respir. Dis. 102:499.[Medline]
  8. Meylan, P. R., D. D. Richman, R. S. Kornbluth. 1990. Characterization and growth in human macrophages of Mycobacterium avium complex strains isolated from the blood of patients with acquired immune deficiency. Infect. Immun. 58:2564.[Abstract/Free Full Text]
  9. Sison, J., Y. Yao, C. Kemper, J. Hamilton, E. Brummer, D. Stevens, S. Deresinski. 1996. Treatment of Mycobacterium avium complex infection: do the results of the in vitro susceptibility tests predict therapeutic outcome in humans?. J. Infect. Dis. 173:677.[Medline]
  10. Barrow, W. W., B. P. Ullom, P. J. Brennan. 1980. Peptidoglycolipid nature of the superficial cell wall sheath of smooth-colony-forming mycobacteria. J. Bacteriol. 144:814.[Abstract/Free Full Text]
  11. Belisle, J. T., P. J. Brennan. 1989. Chemical basis of rough and smooth variation in mycobacteria. J. Bacteriol. 171:3465.[Abstract/Free Full Text]
  12. Barrow, W., P. J. Brennan. 1982. Isolation in high frequency of rough variants of Mycobacterium intracellulare lacking C-mycoside glycopeptidolipid antigens. J. Bacteriol. 150:381.[Abstract/Free Full Text]
  13. Prinzis, S., B. Rivoire, P. J. Brennan. 1994. Search for the molecular basis of morphological variation in Mycobacterium avium. Infect. Immun. 62:1946.[Abstract/Free Full Text]
  14. Pedrosa, J., M. Florido, Z. M. Kunze, A. G. Castro, F. Portaels, J. McFadden, M. T. Silva, R. Appelberg. 1994. Characterization of the virulence of Mycobacterium avium complex (MAC) isolates in mice. Clin. Exp. Immunol 98:210.[Medline]
  15. Appelberg, R., A. G. Castro, J. Pedrosa, R. A. Silva, I. M. Orme, P. Minoprio. 1994. Role of {gamma} interferon and tumor necrosis factor {alpha} during T-cell-independent and -dependent phases of Mycobacterium avium infection. Infect. Immun. 62:3962.[Abstract/Free Full Text]
  16. Appelberg, R., A. Sarmento, A. G. Castro. 1995. Tumour necrosis factor-{alpha} (TNF-{alpha}) in the host resistance to mycobacteria of distinct virulence. Clin. Exp. Immunol 101:308.[Medline]
  17. Furney, S. K., P. S. Skinner, A. D. Roberts, R. Appelberg, I. M. Orme. 1992. Capacity of Mycobacterium avium isolates to grow well or poorly in murine macrophages resides in their ability to induce secretion of tumor necrosis factor. Infect. Immun. 60:4410.[Abstract/Free Full Text]
  18. Sarmento, A. M., R. Appelberg. 1995. Relationship between virulence of Mycobacterium avium strains and induction of tumor necrosis factor {alpha} production in infected mice and in in vitro-cultured mouse macrophages. Infect. Immun. 63:3759.[Abstract]
  19. Shiratsuchi, H., Z. Toosi, M. A. Mettler, J. J. Ellner. 1993. Colonial morphotype as a determinant of cytokine expression by monocytes infected with Mycobacterium avium. J. Immunol. 150:2945.[Abstract]
  20. Fattorini, L., Y. Xiao, B. Li, C. Santoro, F. Ippoliti, G. Orefici. 1994. Induction of IL-1b, IL-6, TNF-{alpha}, GM-CSF, and G-CSF in human macrophages by smooth transparent and smooth opaque colonial variants of Mycobacterium avium. J. Med. Microbiol. 40:129.[Abstract/Free Full Text]
  21. Hobbie, S., L. M. Chen, R. J. Davis, J. E. Galan. 1997. Involvement of mitogen-activated protein kinase pathways in the nuclear responses and cytokine production induced by Salmonella typhimurium in cultured intestinal epithelial cells. J. Immunol. 159:5550.[Abstract]
  22. Ruckdeschel, K., J. Machold, A. Roggenkamp, S. Schubert, J. Pierre, R. Zumbihl, J. P. Liautard, J. Heesemann, B. Rouot. 1997. Yersinia enterocolitica promotes deactivation of macrophage mitogen-activated protein kinases extracellular signal-regulated kinase-1/2, p38, and c-Jun NH2-terminal kinase: correlation with its inhibitory effect on tumor necrosis factor-{alpha} production. J. Biol. Chem. 272:15920.[Abstract/Free Full Text]
  23. Palmer, L. E., S. Hobbie, J. E. Galan, J. B. Bliska. 1998. YopJ of Yersinia pseudotuberculosis is required for the inhibition of macrophage TNF-{alpha} production and downregulation of the MAP kinases p38 and JNK. Mol. Microbiol. 27:953.[Medline]
  24. Palmer, L. E., A. R. Pancetti, S. Greenberg, J. B. Bliska. 1999. YopJ of Yersinia spp. is sufficient to cause downregulation of multiple mitogen-activated protein kinases in eukaryotic cells. Infect. Immun. 67:708.[Abstract/Free Full Text]
  25. Tang, P., I. Rosenshine, P. Cossart, B. B. Finlay. 1996. Listeriolysin O activates mitogen-activated protein kinase in eucaryotic cells. Infect. Immun. 64:2359.[Abstract]
  26. Tang, P., C. L. Sutherland, M. R. Gold, B. B. Finlay. 1998. Listeria monocytogenes invasion of epithelial cells requires the MEK-1/ERK-2 mitogen-activated protein kinase pathway. Infect. Immun. 66:1106.[Abstract/Free Full Text]
  27. Belisle, J. T., P. J. Brennan. 1994. Molecular basis of colony morphology in Mycobacterium avium. Res. Microbiol. 145:237.[Medline]
  28. Rhoades, E. R., I. Orme. 1998. Similar responses by macrophages from young and old mice infected with Mycobacterium tuberculosis. Mech. Ageing Dev. 106:145.[Medline]
  29. Rhoades, E., I. Orme. 1997. Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates. Infect. Immun. 65:1189.[Abstract]
  30. Rao, K.. 2001. MAP kinase activation in macrophages. J. Leukocyte Biol. 69:3.[Abstract/Free Full Text]
  31. Rose, D., B. Winston, E. Chan, D. Riches, P. Gerwins, G. Johnson, P. Henson. 1997. Fc{gamma} receptor cross-linking activates p42, p38, and JNK/SAPK mitogen-activated protein kinases in murine macrophages: role for p42MAPK in Fc{gamma} receptor-stimulated TNF-{alpha} synthesis. J. Immunol. 158:3433.[Abstract]
  32. Song, G., C. Chung, D. Jarrar, I. Chaudry, A. Ayala. 2001. Evolution of an immune suppressive macrophage phenotype as a product of p38 MAPK activation in polymicrobial sepsis. Shock 15:42.[Medline]
  33. De, A., K. Kodys, B. Yeh, C. Miller-Graziano. 2000. Exaggerated human monocyte IL-10 concomitant to minimal TNF-{alpha} induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is primarily an anti-inflammatory stimulus. J. Immunol. 165:3951.[Abstract/Free Full Text]
  34. Lasa, M., K. Mahtani, A. Finch, G. Brewer, J. Saklatvala, A. Clark. 2000. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol. Cell. Biol. 20:4265.[Abstract/Free Full Text]
  35. Hiller, G., R. Sundler. 1999. Activation of arachidonate release and cytosolic phospholipase A2 via extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in macrophages stimulated by bacteria or zymosan. Cell. Signal. 11:863.[Medline]
  36. Lali, F. V., A. Hunt, S. Turner, B. Foxwell. 2000. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J. Biol. Chem. 275:7395.[Abstract/Free Full Text]
  37. Ridgway, D., L. Wolff, M. Wall, M. Borzy, C. Kirkpatrick. 1991. Indomethacin-sensitive monocyte killing defect in a child with disseminated atypical mycobacterial disease. J. Clin. Immunol. 11:357.[Medline]
  38. Denis, M.. 1994. Envelope glycoprotein (gp120) from HIV-1 enhances Mycobacterium avium growth in human bronchoalveolar macrophages: an effect mediated by enhanced prostaglandin synthesis. Clin. Exp. Immunol. 98:123.[Medline]
  39. Pouliot, M., J. Baillargeon, J. Lee, L. Cleland, M. James. 1997. Inhibition of prostaglandin endoperoxidase synthase-2 expression in stimulated human monocytes by inhibitors of p38 mitogen-activated protein kinase. J. Immunol. 158:4930.[Abstract]
  40. Cuenda, A., J. Rouse, Y. Doza, R. Meier, P. Cohen, T. Gallagher, P. Young, J. Lee. 1995. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364:229.[Medline]
  41. Borsch-Haubold, A., S. Pasquet, S. Watson. 1998. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059: SB 203580 also inhibits thromboxane synthase. J. Biol. Chem. 273:28766.[Abstract/Free Full Text]
  42. Whitmarsh, A. J., S. Yang, M. Su, A. Sharrocks, R. Davis. 1997. Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors. Mol. Cell. Biol. 17:2360.[Abstract]
  43. Fratazzi, C., R. D. Arbeit, C. Carini, M. K. Balcewicz-Sabliska, J. Keane, H. Kornfeld, H. G. Remold. 1999. Macrophage apoptosis in mycobacterial infection. J. Leukocyte Biol. 66:763.[Abstract]
  44. Bermudez, L. E., A. Parker, M. Petrofsky. 1999. Apoptosis of Mycobacterium avium-infected macrophages is mediated by both tumour necrosis factor (TNF) and Fas, and involves the activation of caspases. Clin. Exp. Immunol. 116:94.[Medline]
  45. Gan, H., G. Newman, H. Remold. 1995. Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with Mycobacterium avium, serovar 4. J. Immunol. 155:1304.[Abstract]
  46. Zimmermann, S., K. Moelling. 1999. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286:1741.[Abstract/Free Full Text]
  47. Rommel, C., B. Clarke, S. Zimmermann, L. Nunez, R. Rossman, K. Reid, K. Moelling, G. Yancopoulos, D. Glass. 1999. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286:1741.
  48. Feng, G. J., H. Goodridge, M. Harnett, X. Wei, A. Nikolaev, A. Higson, F. J. I. Liew. 1999. Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J. Immunol. 163:6403.[Abstract/Free Full Text]
  49. Singh, R. P., P. Dhawan, C. Golden, G. Kapoor, K. Mehta. 1999. One-way cross-talk between p38MAPK and p42/44MAPK: inhibition of p38MAPK induces low density lipoprotein receptor expression through activation of the p42/44MAPK cascade. J. Biol. Chem. 274:19593.[Abstract/Free Full Text]
  50. Chan, E. D., D. Riches. 2001. IFN-{gamma} plus LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38MAPK in a mouse macrophage cell line. Am. J. Physiol. 280:C441.



This article has been cited by other articles:


Home page
Infect. Immun.Home page
D. E. Voth and R. A. Heinzen
Sustained Activation of Akt and Erk1/2 Is Required for Coxiella burnetii Antiapoptotic Activity
Infect. Immun., January 1, 2009; 77(1): 205 - 213.
[Abstract] [Full Text] [PDF]


Home page
Vet PatholHome page
D. J. Weiss and C. D. Souza
REVIEW PAPER: Modulation of Mononuclear Phagocyte Function by Mycobacterium avium subsp. paratuberculosis
Vet. Pathol., November 1, 2008; 45(6): 829 - 841.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
A. Welin, M. E. Winberg, H. Abdalla, E. Sarndahl, B. Rasmusson, O. Stendahl, and M. Lerm
Incorporation of Mycobacterium tuberculosis Lipoarabinomannan into Macrophage Membrane Rafts Is a Prerequisite for the Phagosomal Maturation Block
Infect. Immun., July 1, 2008; 76(7): 2882 - 2887.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Yamashita, T. Shinohara, S. Tsuji, Q. N. Myrvik, A. Nishiyama, R. A. Henriksen, and Y. Shibata
Catalytically Inactive Cyclooxygenase 2 and Absence of Prostaglandin E2 Biosynthesis in Murine Peritoneal Macrophages following In Vivo Phagocytosis of Heat-Killed Mycobacterium bovis Bacillus Calmette-Guerin
J. Immunol., November 15, 2007; 179(10): 7072 - 7078.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Wittkowski, J. Mittelstadt, S. Brandau, N. Reiling, B. Lindner, J. Torrelles, P. J. Brennan, and O. Holst
Capsular Arabinomannans from Mycobacterium avium with Morphotype-specific Structural Differences but Identical Biological Activity
J. Biol. Chem., June 29, 2007; 282(26): 19103 - 19112.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Yadav, L. Clark, and J. S. Schorey
Macrophage's Proinflammatory Response to a Mycobacterial Infection Is Dependent on Sphingosine Kinase-Mediated Activation of Phosphatidylinositol Phospholipase C, Protein Kinase C, ERK1/2, and Phosphatidylinositol 3-Kinase
J. Immunol., May 1, 2006; 176(9): 5494 - 5503.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
P. T. G. Elkington, R. K. Nuttall, J. J. Boyle, C. M. O'Kane, D. E. Horncastle, D. R. Edwards, and J. S. Friedland
Mycobacterium tuberculosis, but Not Vaccine BCG, Specifically Upregulates Matrix Metalloproteinase-1
Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1596 - 1604.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
A. Blumenthal, J. Lauber, R. Hoffmann, M. Ernst, C. Keller, J. Buer, S. Ehlers, and N. Reiling
Common and Unique Gene Expression Signatures of Human Macrophages in Response to Four Strains of Mycobacterium avium That Differ in Their Growth and Persistence Characteristics
Infect. Immun., June 1, 2005; 73(6): 3330 - 3341.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. K. Pathak, A. Bhattacharyya, S. Pathak, C. Basak, D. Mandal, M. Kundu, and J. Basu
Toll-like Receptor 2 and Mitogen- and Stress-activated Kinase 1 Are Effectors of Mycobacterium avium-induced Cyclooxygenase-2 Expression in Macrophages
J. Biol. Chem., December 31, 2004; 279(53): 55127 - 55136.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. E. Pearl, S. A. Khader, A. Solache, L. Gilmartin, N. Ghilardi, F. deSauvage, and A. M. Cooper
IL-27 Signaling Compromises Control of Bacterial Growth in Mycobacteria-Infected Mice
J. Immunol., December 15, 2004; 173(12): 7490 - 7496.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Yadav, S. K. Roach, and J. S. Schorey
Increased Mitogen-Activated Protein Kinase Activity and TNF-{alpha} Production Associated with Mycobacterium smegmatis- but Not Mycobacterium avium-Infected Macrophages Requires Prolonged Stimulation of the Calmodulin/Calmodulin Kinase and Cyclic AMP/Protein Kinase A Pathways
J. Immunol., May 1, 2004; 172(9): 5588 - 5597.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
C. T. Welsh, J. T. Summersgill, and R. D. Miller
Increases in c-Jun N-Terminal Kinase/Stress-Activated Protein Kinase and p38 Activity in Monocyte-Derived Macrophages following the Uptake of Legionella pneumophila
Infect. Immun., March 1, 2004; 72(3): 1512 - 1518.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
C.-H. Song, J.-S. Lee, H.-J. Kim, J.-K. Park, T.-H. Paik, and E.-K. Jo
Interleukin-8 Is Differentially Expressed by Human-Derived Monocytic Cell Line U937 Infected with Mycobacterium tuberculosis H37Rv and Mycobacterium marinum
Infect. Immun., October 1, 2003; 71(10): 5480 - 5487.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
A. L. K. Hestvik, Z. Hmama, and Y. Av-Gay
Kinome Analysis of Host Response to Mycobacterial Infection: a Novel Technique in Proteomics
Infect. Immun., October 1, 2003; 71(10): 5514 - 5522.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
T. R. M. da Silva, J. R. de Freitas, Q. C. Silva, C. P. Figueira, E. Roxo, S. C. Leao, L. A. R. de Freitas, and P. S. T. Veras
Virulent Mycobacterium fortuitum Restricts NO Production by a Gamma Interferon-Activated J774 Cell Line and Phagosome-Lysosome Fusion
Infect. Immun., October 1, 2002; 70(10): 5628 - 5634.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H.-S. Choi, P. R. Rai, H. W. Chu, C. Cool, and E. D. Chan
Analysis of Nitric Oxide Synthase and Nitrotyrosine Expression in Human Pulmonary Tuberculosis
Am. J. Respir. Crit. Care Med., July 15, 2002; 166(2): 178 - 186.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tse, H. M.
Right arrow Articles by Cooper, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tse, H. M.
Right arrow Articles by Cooper, A. M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS